Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remicade for Toxic Epidermal Necrolysis
NCT00372723Phase 2Withdrawn
- Sponsor
- Loyola University Chicago
- Start
- Jul 2006
- Primary completion
- Jun 2011
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of infliximab in toxic epidermal necrolysis (TEN), sponsored by Loyola University Chicago. Primary endpoint: 30 day mortality. Planned start Jul 2006; status: withdrawn.
02
Drugs
infliximab
03
Conditions
toxic epidermal necrolysis (TEN)
Beyond the preview
Go deeper on NCT00372723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00372723.